Thromb Haemost 1996; 76(05): 715-719
DOI: 10.1055/s-0038-1650649
Original Article
Schattauer GmbH Stuttgart

Antagonism of SR 90107A/Org 31540-lnduced Bleeding by Protamine Sulfate in Rats and Mice

A Bernat
Sanofi Recherche, Toulouse, France
,
P Hoffmann
Sanofi Recherche, Toulouse, France
,
J M Herbert
Sanofi Recherche, Toulouse, France
› Author Affiliations
Further Information

Publication History

Received 20 March 1996

Accepted after resubmission 22 July 1996

Publication Date:
11 July 2018 (online)

Summary

The neutralization by protamine sulfate of bleeding enhancement induced by the potent anti-factor Xa pentasaccharide SR 90107A/Org 31540 and by heparin has been studied in rats and mice. Bleeding, as measured by transection of the tail of anaesthetised rats or mice, was increased following the administration of heparin and very high doses of SR 90107A/Org 31540. In rats, i.v. doses of 0.6 mg/kg heparin or 15 mg/kg SR 90107A/Org 31540 were required to enhance bleeding time to approximately the same extent (5- or 7-fold increase), whereas in mice a 13-fold increase in blood loss was observed with i.v. doses of 3 mg/kg heparin or 10 mg/kg SR 90107A/Org 31540. Protamine sulfate (10 mg/kg i.v.) reduced bleeding in rats and mice induced by both compounds. It also neutralized the anti-factor Xa activity as well as the antithrombotic activity of heparin as observed in venous thrombosis models in both species. However, protamine sulfate neither affected the anti-factor Xa activity nor the antithrombotic activity of SR 90107A/Org 31540 in rats and mice. The present results suggest that protamine sulfate may be regarded as a potential antidote to neutralize bleeding side-effects in cases of SR 90107A/Org 31540 overdosing.

 
  • References

  • 1 Van Ryn-McKenna J, Ofosu FA, Hirsh J, Buchanan MR. Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphation. Br J Haematol 1989; 71: 265-269
  • 2 Fernandez F, Nguyen P, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 1986; 43: 491-495
  • 3 Dutton DA, Hotersall AP, Me Laren AD, Taylor KM, Turner MA. Protamine titration after cardiopulmonary bypass. Anaesthesia 1983; 38: 264-268
  • 4 Diness V, Østergaard PB. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats. Thromb Haemost 1986; 56: 318-322
  • 5 Bang CJ, Berstad A, Talstad I. Incomplete reversal of enoxaparin-induced bleeding by protamine sulfate. Haemostasis 1991; 21: 155-160
  • 6 Doutremepuich C, Bonini F, Toulemonde tF, Bertrand H, Bayrou B, Quili-chini R. In vivo neutralization of low-molecular weight heparin fraction CY 216 by protamine. Sem Thromb Haemost 1985; 11: 318-322
  • 7 Van Ryn-McKenna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR. Neutralization of enoxaparine-induced bleeding by protamine sulfate. Thromb Haemost 1990; 63: 271-274
  • 8 Racanelli A, Fareed J. Neutralization of the antithrombotic effects of heparin and fraxiparin by protamine sulfate. Thromb Res 1992; 68: 211-222
  • 9 Choay J, Petitou M, Lormeau JC, Sinay P, Casu BJ, Gatt G. Structure-activ-ity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Comm 1983; 116: 492-499
  • 10 Hobbelen PMJ, van Dinther TG, Vogel GMT, van Boeckel CAA, Moelker HCT, Meuleman DG. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb Haemost 1990; 63: 265-270
  • 11 Bernat A, Herbert JM. Protamine sulfate inhibits pentasaccharide (SR 80027)-induced bleeding without affecting its antithrombotic and antifactor Xa activity in the rat. Haemostasis 1996; 26: 195-202
  • 12 Vogel GMT, Meuleman DG, Bourgondien FG, Hobbelen M. Comparison of two experimental thrombosis models in rats, effects of four glycosaminoglycans. Thromb Res 1989; 54: 399-410
  • 13 Dejana E, Callioni A, Quintana A, De Gaetano G. Bleeding time in laboratory animals II. A comparison of different assay conditions in rats. Thromb Res 1979; 15: 191-197
  • 14 Herbert JM, Bernat A, Maffrand JP. Aprotinin reduces clopidogrel-induced prolongation of the bleeding time in the rat. Thromb Res 1993; 71: 433-441
  • 15 Jaques V, Kavanagh LW. Protamine neutralization factors for heparin. Can J Pharm Sci 1977; 12: 44-47
  • 16 Planes A, Vochelle N, Mazas C, Zucman J, Landais A, Pascariello JC, Weill D, Butel J. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988; 60: 407-410
  • 17 van Amsterdam RGM, Vogel GMT, Visser A, Kop WJ, Buiting MT, Meuleman DG. Synthetic analogues of the antithrombin Ill-binding pentasaccharide sequence of heparin. Prediction of in vivo residence times. Arterioscler Thromb Vascul Biol 1995; 15: 495-503
  • 18 Racanelli A, Fareed J. Neutralization of the antithrombotic effects of heparin and fraxiparin by protamine sulfate. Thromb Res 1992; 68: 211-222
  • 19 Horrow JC. Protamine: a review of its toxicity. Anesth Anal 1984; 64: 348-357
  • 20 Lindblad B. Protamine sulfate: a review of its effects, hypersensitivity and toxicity. Eur J Vase Surg 1989; 3: 195-201